Janux stock plunges after hours following mCRPC trial data
DURHAM, N.C./SEOUL - Lunit (KRX:328130) and Labcorp announced Monday a collaborative initiative to advance digital pathology and artificial intelligence technologies for oncology research and clinical care. Lunit, a prominent player in the Health Care Technology industry according to InvestingPro, has seen its stock take a significant hit over the last week despite its strategic partnerships.
The partnership combines Labcorp's clinical and pathology expertise with Lunit's AI algorithms to enhance analysis of tumor microenvironments. The collaboration aims to improve biomarker discovery and precision immuno-oncology approaches through AI-powered spatial profiling and high-resolution whole-slide imaging.
Initial results from the collaboration were presented at two scientific conferences. At the Society for Immunotherapy of Cancer (SITC), researchers demonstrated how AI-based spatial profiling identified immune-active subtypes of non-small cell lung cancer tumors with MET exon 14 skipping mutations that showed improved immunotherapy outcomes. The study analyzed over 370 pathology slides using Lunit SCOPE IO.
A separate study presented at the Association for Molecular Pathology (AMP) revealed distinct tumor-immune microenvironments associated with different MET alterations in non-small cell lung cancer.
"These early studies show how AI can reveal meaningful, predictive biomarkers hidden within pathology slides," said Brandon Suh, CEO of Lunit, in the press release.
Shakti Ramkissoon, vice president and medical lead for oncology at Labcorp, stated the collaboration "aims to turn complex pathology data into meaningful insights."
The companies plan to expand their work by applying digital pathology AI to additional cancer types and genomic correlations, according to the announcement. Despite current financial challenges, Lunit has demonstrated strong returns over the last five years. InvestingPro offers 8 additional tips about Lunit's valuation multiples and future prospects that could be valuable for investors monitoring this emerging healthcare technology player.
In other recent news, Lunit and Agilent Technologies have announced a collaboration to develop AI-based companion diagnostic solutions for biomarker testing. This partnership aims to integrate Lunit's artificial intelligence algorithms with Agilent's tissue-based diagnostic assays. The goal is to create tools that enhance the accuracy of diagnoses and measure the efficacy of therapies. Initially, the collaboration will focus on developing AI-powered assays for use in research and clinical trials. These recent developments highlight the growing intersection of artificial intelligence and healthcare diagnostics. The nonexclusive nature of this partnership allows both companies to explore further opportunities in the diagnostic field. Investors may find this collaboration noteworthy as it represents a significant step in advancing diagnostic technology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.